GlassScriptPhysician profile
Hamid J Obeid
NPI 1548251663
$15,361.08
in general payments reported to CMS, 2019-2025
26 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what 88% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $826 · 2021: $1,766 · 2022: $5,580 · 2023: $1,185 · 2024: $2,813 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,550 · Travel and Lodging: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,550.09 |
| Travel and Lodging | $2,312.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,926.97 | 2021-2022 | |
| Aerin Medical INC. | $2,224.10 | 2020-2025 | |
| Integra Lifesciences Corporation | $1,360.37 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Astrazeneca Pharmaceuticals LP | $1,224.90 | 2019-2025 | Fasenra, Breztri, Symbicort |
| Glaxosmithkline, LLC. | $1,043.94 | 2019-2025 | Nucala |
| Intersect Ent, INC. | $899.69 | 2019-2022 | |
| Acclarent, INC | $890.50 | 2019-2023 | Acclarent Navwire, Acclarent Aera, Relieva Tract |
| Medical Device Business Services, INC. | $826.00 | 2022 | |
| Medtronic USA, INC. | $611.84 | 2019-2020 | |
| Genzyme Corporation | $609.66 | 2019-2025 | |
| Optinose US, INC. | $495.55 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $422.52 | 2019-2025 | Dupixent |
| Smith+Nephew, INC. | $171.27 | 2019-2023 | Ent Sinus, Halo, Rapid Rhino |
| Biohaven Pharmaceuticals, INC. | $132.70 | 2021 | |
| Alk-Abello, INC | $114.34 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $75.08 | 2023 | Pentaray Nav |
| Stryker Corporation | $66.24 | 2019-2023 | Entellus Medical Reinforced Anesthesia Needle, Xpress Ent Dilation System |
| Arbor Pharmaceuticals, INC. | $45.76 | 2019 | |
| Allergan, INC. | $45.75 | 2021 | |
| Olympus America INC. | $33.64 | 2019 | |
| Neurent Medical Limited | $32.14 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Acelrx Pharmaceuticals, INC. | $30.33 | 2022 | |
| Mdd US Operations, LLC | $30.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.21 | 2019 | |
| Ambu INC. | $17.59 | 2024 | |
| Musculoskeletal Transplant Foundation INC. | $6.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Obeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.